The US dietary supplement industry’s success could make Food and Drug Administration regulations for its products vulnerable to challenge with the Supreme Court striking the Chevron doctrine of deference, particularly a rule considered the chief impediment to further growth.
“This is an industry that has been, that has been really concerned about FDA, about this drug preclusion provision, about FDA decision-making
“Dietary supplement manufacturing, labeling and marketing will be particularly vulnerable given the exponential increase globally in the production of such products over the past 20 years,” said attorney Maribeth